BioSpace News Archive

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, announced the appointment of Thomas Schlumpberger, Ph.D., as Executive Vice President, Diagnostics.

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results.

Gencove, the leading low-pass genome sequencing technology provider, announced today the launch of the first enterprise-ready low-pass sequencing analysis platform.

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients

Approximately 300 Physicians Registered to Attend Axonics-sponsored Seminars Showcasing Recently FDA-Approved1 Axonics r-SNM® System

Avivagen Inc. announced that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 1,163,738 common shares at $1.00 per share which were originally issued on December 16, 2014 and warrants exercisable to purchase 2,774,991 common shares at $0.90 per share which were originally issued on June 1, 2016.

Johnson & Johnson announced results for third-quarter 2019.

Nabriva Therapeutics plc announced that it will present data on the pooled results from completed Phase 3 trials of XENLETA™ at the CHEST Annual Meeting 2019, to be held October 19-23 in New Orleans.

Landos Biopharma announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conferences.

Novavax, Inc. announced the initiation of a pivotal Phase 3 clinical trial for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, in adults aged 65 and over.